Full Text View
Tabular View
Contacts and Locations
No Study Results Posted
Related Studies
Screen and Treat for Cervical Cancer Prevention
This study has been completed.
Sponsors and Collaborators: Columbia University
Bill and Melinda Gates Foundation
Engender Health, New York
University of Cape Town
Information provided by: Columbia University
ClinicalTrials.gov Identifier: NCT00233727
  Purpose

The study measures the impact of "screen–and-treat" on the prevalence of high-grade cervical intraepithelial neoplasia and cancer (CIN 2+). It is a three-arm, randomized clinical trial comparing two “screen-and-treat” approaches to delayed evaluation as a control. The primary outcome is biopsy-confirmed CIN 2+ at 6 months and significant complications within 6 months of randomization with continued follow-up to detect CIN2+ and other complications up to 36 months post-randomization.


Condition Intervention Phase
Cervical Cancer
Procedure: Screen (VIA or HPV) then treat with cryotherapy
Phase III

MedlinePlus related topics: Cancer
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Safety and Efficacy of Two Screen-and-Treat Approaches for the Prevention of Cervical Cancer

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • cervical intraepithelial neoplasia (CIN) grade 2 or 3 or cervical cancer

Secondary Outcome Measures:
  • HIV incidence
  • severe adverse events e.g. bleeding, infection

Estimated Enrollment: 7200
Study Start Date: January 2000
Estimated Study Completion Date: April 2006
Detailed Description:

Participants and Clinical Examinations: Unscreened, non-pregnant women 35-65 years of age are enrolled at three closely located clinical sites in Khayelitsha, South Africa. All women provide informed consent, receive counseling for confidential HIV serotesting, a questionnaire, a pregnancy test if not postmenopausal, anonymous HIV serotesting, and a vaginal speculum examination by nurses trained in visual inspection of the cervix with acetic acid (VIA). Cervical specimens are obtained for testing for N. gonorrhea, Chlamydia trachomatis and high-risk types of HPV, and cytology. The cervix is washed with 5% acetic acid and inspected for gross abnormalities or areas of acetowhitening and a 35 mm. photograph taken. Women with significant cervicitis or vulvovaginitis are treated using the syndromic approach. N. gonorrhea or Chlamydia trachomatis positive women receive appropriate therapy. A positive VIA examination is defined as any acetowhite lesion and no attempt is made to differentiate the acetowhitening of metaplasia from CIN. Women with lesions suspicious for cancer, large acetowhite lesions extending over 70% of the cervix or into endocervical canal, and 374 unsuitable for cryotherapy due to severe atrophy, polyps, cervix distorted, cervix not adequately visualized are excluded. These women are referred to colposcopy.

Women are asked to return 2–6 days later for randomization to either: (1) HPV arm in which all HPV DNA positive women receive cryotherapy; (2) VIA arm in which all VIA positive women receive cryotherapy; and (3) a delayed evaluation arm in which women are followed untreated, irrespective of HPV or VIA status. Randomization is done at a patient level using a computer-generated randomization schedule with arm assignments provided to the clinics in sealed envelopes. Cryotherapy is performed by a nurse using N2O and a cryosurgical unit (Wallach Surgical Devices, Orange, CT) using two 3-minute freezes. Cytology results are not available at the time of cryotherapy. Both treated and untreated women are asked to return at 4 weeks for a questionnaire.

At 6 months, colposcopy is done by a physician blinded to arm and clinical information. All acetowhite lesions are biopsied and all have an endocervical curettage. Women with CIN 2+ are treated with LEEP. Examinations in women who became pregnant during the study are postponed until three months post-partum. Blood for anonymous HIV serotesting is obtained. All women who were HPV or VIA-positive at enrollment and a subset who were HPV and VIA-negative (all women enrolled in 2002) are scheduled for repeat colposcopy at 12 months, 24 months and 36 months post-randomization. At these visits, cervical samples are collected and colposcopy and biopsy if indicated is performed.

Laboratory Testing: HPV testing is done using the Hybrid Capture 2 HPV DNA assay and high-risk probe mixture (Digene Corporation, Gaithersburg, MD) at the University of Cape Town. Biopsies are processed at Columbia University and blindly evaluated by a single pathologist.

  Eligibility

Ages Eligible for Study:   35 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • • Never been screened for cervical cancer

    • Not currently pregnant

Exclusion Criteria:

  • • Have lesions suspicious for cancer, have large acetowhite lesions extending over 70% of the cervix or into endocervical canal, are unsuitable for cryotherapy because of severe atrophy, polyps, cervix distorted, cervix cannot be adequately visualized
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00233727

Locations
South Africa, Western Cape
University of Cape Town
Cape Town, Western Cape, South Africa, 8001
Sponsors and Collaborators
Columbia University
Bill and Melinda Gates Foundation
Engender Health, New York
University of Cape Town
Investigators
Study Director: Lynette Denny, MD University of Cape Town
Principal Investigator: Thomas C Wright, MD Columbia University
  More Information

Publications of Results:
Study ID Numbers: Screen and Treat (SAT), Funded by Gates Foundation
Study First Received: October 4, 2005
Last Updated: May 5, 2006
ClinicalTrials.gov Identifier: NCT00233727  
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
cervical cancer
cervical intraepithelial neoplasia
prevention
cryotherapy
HPV testing
cytology

Study placed in the following topic categories:
Cervical intraepithelial neoplasia
Cervical Intraepithelial Neoplasia

ClinicalTrials.gov processed this record on February 12, 2009